{"id":"hzt-501","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HZT-501 functions as a bispecific antibody designed to bind two different targets on immune cells, thereby co-stimulating T-cell activation and proliferation. By bridging multiple immune checkpoints or costimulatory pathways, the drug aims to overcome tumor immune evasion and drive more potent anti-cancer immunity than single-target approaches.","oneSentence":"HZT-501 is a bispecific antibody that simultaneously engages two distinct immune pathways to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:24.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT00984815","phase":"PHASE3","title":"Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-09","conditions":"Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain","enrollment":86},{"nctId":"NCT00613106","phase":"PHASE3","title":"Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-09","conditions":"Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain","enrollment":179},{"nctId":"NCT00450658","phase":"PHASE3","title":"Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-03","conditions":"Peptic Ulcer","enrollment":627},{"nctId":"NCT00450216","phase":"PHASE3","title":"Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-03","conditions":"Ulcer","enrollment":906}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HZT-501","genericName":"HZT-501","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HZT-501 is a treatment being studied for various conditions, including Ulcer, Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, and Chronic Regional Pain Syndrome. It is a medication that requires nonsteroidal anti-inflammatory drug (NSAID) treatment, as indicated by a randomized, double-blind, Phase 3 study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}